SCHEDULE 13G/A 0001104659-24-107836 0000901832 XXXXXXXX LIVE 1 Common Stock, par value $0.0001 per share 03/31/2025 0001896212 Conduit Pharmaceuticals Inc. 20678X106 4851 Tamiami Trail North Suite 200 Naples FL 34103 Rule 13d-1(c) AstraZeneca PLC b X0 73892.00 0.00 73892.00 0.00 73892.00 N 1.1 CO 1 Represents shares directly held by AstraZeneca AB, a wholly-owned subsidiary of AstraZeneca PLC. AstraZeneca PLC and AstraZeneca AB may each be deemed to have sole voting and dispositive power over the shares. 2 See footnote 1. 3 See footnote 1. 4 The percentage ownership was calculated based on 6,662,755 shares of the issuer's common stock outstanding as of March 28, 2025, as reported in the issuer's Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 28, 2025. AstraZeneca AB b V7 73892.00 0.00 73892.00 0.00 73892.00 N 1.1 CO 5 See footnote 1. 6 See footnote 1. 7 See footnote 1. 8 See footnote 4. Conduit Pharmaceuticals Inc. 4851 Tamiami Trail North, Suite 200 Naples, FL, 34103 See response to 2(c) See response to 2(c) This statement is filed on behalf of: AstraZeneca PLC 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom Citizenship: United Kingdom AstraZeneca AB SE-151 85 Sodertalje Sweden Citizenship: Sweden Y 73,892 1.1%. The percentage stated herein is based on 6,662,755 shares of the issuer's common stock outstanding as of March 28, 2025, as reported in the issuer's Form 10-K filed with the SEC on March 28, 2025. AstraZeneca PLC: 73,892 shares AstraZeneca AB: 73,892 shares AstraZeneca PLC: 0 shares AstraZeneca AB: 0 shares AstraZeneca PLC: 73,892 shares AstraZeneca AB: 73,892 shares AstraZeneca PLC: 0 shares AstraZeneca AB: 0 shares N Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. AstraZeneca PLC /s/ Adrian Kemp 04/10/2025 AstraZeneca AB /s/ Lars-Johan Cederbrant 04/10/2025